Aliases & Classifications for Eyelid Disease

MalaCards integrated aliases for Eyelid Disease:

Name: Eyelid Disease 12 15
Eyelid Diseases 44 73
Abnormality of the Eyelid 29
Eyelid Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:530
ICD9CM 35 374.9
MeSH 44 D005141
NCIt 50 C26768
UMLS 73 C0015423

Summaries for Eyelid Disease

MedlinePlus : 43 Your eyelids help protect your eyes. When you blink, your eyelids spread moisture over your eyes. Blinking also helps move dirt or other particles off the surface of the eye. You close your eyelids when you see something coming toward your eyes. This can help protect against injuries. Like most other parts of your body, your eyelids can get infected, inflamed, or even develop cancer. There are also specific eyelid problems, including Eyelids that turn in or out Eyelids that droop Abnormal blinking or twitching Treatment of eyelid problems depends on the cause.

MalaCards based summary : Eyelid Disease, also known as eyelid diseases, is related to ohdo syndrome, sbbys variant and ohdo syndrome, and has symptoms including eye manifestations, lid retraction or lag and eyelid pain. An important gene associated with Eyelid Disease is FOXL2 (Forkhead Box L2). The drugs Lidocaine and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include the eyelid, eye and skin, and related phenotypes are Decreased viability of wild-type and TP53 knockout cells, decreased TP53 protein expression ratio (wild-type / TP53 knockout cells) and behavior/neurological

Disease Ontology : 12 An adnexa disease that is located in the eyelid.

Wikipedia : 76 An eyelid is a thin fold of skin that covers and protects the human eye. The levator palpebrae... more...

Related Diseases for Eyelid Disease

Graphical network of the top 20 diseases related to Eyelid Disease:



Diseases related to Eyelid Disease

Symptoms & Phenotypes for Eyelid Disease

UMLS symptoms related to Eyelid Disease:


eye manifestations, lid retraction or lag, eyelid pain

GenomeRNAi Phenotypes related to Eyelid Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability of wild-type and TP53 knockout cells, decreased TP53 protein expression ratio (wild-type / TP53 knockout cells) GR00196-A-1 9.02 COPB2 FOXL2 LAX1 SHOX2 UBE3B

MGI Mouse Phenotypes related to Eyelid Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.23 ABCA12 COPB2 DRD5 HSPG2 MBD5 SCARF2

Drugs & Therapeutics for Eyelid Disease

Drugs for Eyelid Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
2
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
3
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
4
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
5
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
6
Tetracycline Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 60-54-8 5353990
7
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
9
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
10
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
11
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
12
Ephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 299-42-3 9294
13
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 90-82-4 7028
14
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 5496 36294
15
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
16
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
17
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
18
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
19
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 298 5959
20
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
21
Chloramphenicol succinate Experimental Phase 4 3544-94-3
22 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
23 Respiratory System Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Central Nervous System Depressants Phase 4,Not Applicable
25 Adrenergic Agents Phase 4,Not Applicable
26 Adrenergic Agonists Phase 4,Not Applicable
27 Adrenergic alpha-Agonists Phase 4,Not Applicable
28 Adrenergic beta-Agonists Phase 4,Not Applicable
29 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Mydriatics Phase 4,Not Applicable
31 Sodium Channel Blockers Phase 4,Phase 2,Not Applicable
32 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Anesthetics Phase 4,Not Applicable
36 Anesthetics, Local Phase 4,Not Applicable
37 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
38 Ophthalmic Solutions Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Diuretics, Potassium Sparing Phase 4,Phase 2,Not Applicable
40 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Arrhythmia Agents Phase 4,Phase 2,Not Applicable
42 Anti-Asthmatic Agents Phase 4,Not Applicable
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
45 Epinephryl borate Phase 4,Not Applicable
46 Antibiotics, Antitubercular Phase 4,Phase 3,Not Applicable
47 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
49 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Not Applicable
50 Lubricant Eye Drops Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 Botulinum Toxin to Improve Lower Blepharoplasty Scar Unknown status NCT02786550 Phase 4 Botulinum Toxin
2 Saline Injection - Assisted Anesthesia in Eyelid Surgery Unknown status NCT01239498 Phase 4
3 Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases Completed NCT01189474 Phase 4
4 Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases Completed NCT01091311 Phase 4
5 Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis Completed NCT01478256 Phase 4 Erythromycin;Besifloxocin
6 Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis Completed NCT01357538 Phase 4 Posiformin 2 %, bibrocathol;Placebo Comparator
7 Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm Completed NCT01259557 Phase 4 Botulinum Toxin Type A
8 Lipids of the Human Tear Film and Their Effect on Tear Stability Completed NCT00803452 Phase 4 doxycycline;azithromycin
9 Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Completed NCT00761592 Phase 4
10 Efficacy of Aurosling in Frontalis Sling Suspension Surgery Completed NCT00753831 Phase 4
11 Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis Completed NCT00656539 Phase 4 AzaSite®
12 Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis Completed NCT00629980 Phase 4 AzaSite®
13 Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis Completed NCT00629941 Phase 4 AzaSite®
14 Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis Completed NCT00629590 Phase 4 AzaSite®
15 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia Completed NCT00347776 Phase 4 azithromycin;topical tetracycline
16 Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
17 Vibration-Assisted Anaesthesia Completed NCT00793988 Phase 4
18 Pediatric Zylet Safety and Efficacy Study Completed NCT00420628 Phase 4 loteprednol etabonate/tobramycin opthalmic suspension;vehicle
19 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
20 Topical Antibiotic Prophylaxis for Eyelids Recruiting NCT03199911 Phase 4 Topical Anti-Infective Product;Topical Ointment
21 Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Active, not recruiting NCT03508882 Phase 4 Botulinum Toxin Type A 100Unit/Vial (Product);Saline Solution for Injection
22 The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis Enrolling by invitation NCT03105505 Phase 4 Permethrin 5%;Synthomycine 5%;Fusidic Acid 1% M/R Eye Drops
23 PMCF-study Using Novosyn® Quick Suture Material in Ophthalmic Surgery Withdrawn NCT02761083 Phase 4
24 Hyaluronic Acid Gels for Lower Lid Retraction Withdrawn NCT01838252 Phase 4
25 Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage Unknown status NCT00534391 Phase 3 neomycin sulfate, polymyxin B sulfate and gramicidin;Artificial tear
26 Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm Completed NCT03216473 Phase 3 Neuronox;Botox
27 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis Completed NCT02436759 Phase 3 RVL-1201;RVL-1201 Vehicle Placebo
28 Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1% Completed NCT02236403 Phase 3 Ivermectin 0.1% Metronidazole 1%
29 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid Completed NCT01896895 Phase 3 IncobulinumtoxinA (Xeomin), 25 Units;IncobotulinumtoxinA (Xeomin), 12.5 Units;Placebo;IncobotulinumtoxinA (Xeomin), 35 Units
30 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm Completed NCT01791881 Phase 3 Hugeltox;Botulinum Toxin Type A(Botox®)
31 Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis Completed NCT01408082 Phase 3 ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined);Azasite;Dexamethasone
32 A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis Completed NCT01102244 Phase 3 Tobradex ST;Azasite
33 Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Completed NCT00682760 Phase 3 Korean Botulinum toxin type A (KbtxA) and Botox injection
34 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Completed NCT00406367 Phase 3 incobotulinumtoxinA (Xeomin);Placebo
35 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Completed NCT01028027 Phase 3 Loteprednol and tobramycin;Tobramycin and dexamethasone
36 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
37 Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Completed NCT00796926 Phase 3 Systane Ultra eyedrops;Refresh eye drops
38 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Completed NCT01202747 Phase 2, Phase 3
39 Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis Recruiting NCT03565887 Phase 3 RVL-1201
40 Study of Safety of RVL-1201 in Treatment of Blepharoptosis Recruiting NCT03536949 Phase 3 RVL-1201
41 Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Recruiting NCT02947815 Phase 2, Phase 3 Clostridium Botulinum Toxin Type A;Clostridium Botulinum Toxin Type A
42 Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects Recruiting NCT01543490 Phase 3 ISV-305
43 Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion Recruiting NCT03248440 Phase 3 SUN-131 1.5% TDS;Placebo TDS
44 Chalazia Treatment Study Recruiting NCT02025023 Phase 3 5-fluorouracil Injection;Triamcinolone Acetonide;Triamcinolone Acetonide/5-fluorouracil mixture
45 Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
46 Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Completed NCT02218489 Phase 2 KPI-121;Vehicle
47 Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis Completed NCT01848041 Phase 1, Phase 2 RVL-1201;RVL-1201 Vehicle Placebo
48 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis Completed NCT01783860 Phase 2 Azithromycin;Doxycycline
49 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Completed NCT01089608 Phase 2 Azithromycin;Povidone
50 Tea Tree Oil in the Treatment of Chronic Blepharitis Completed NCT01073150 Phase 2 Tea Tree Oil

Search NIH Clinical Center for Eyelid Disease

Cochrane evidence based reviews: eyelid diseases

Genetic Tests for Eyelid Disease

Genetic tests related to Eyelid Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Eyelid 29

Anatomical Context for Eyelid Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Eyelid Disease:

19
The Eyelid

MalaCards organs/tissues related to Eyelid Disease:

41
Eye, Skin, Brain, Testes, Breast

Publications for Eyelid Disease

Articles related to Eyelid Disease:

# Title Authors Year
1
Metastatic eyelid disease associated with primary breast carcinoma: case report. ( 19668974 )
2009
2
Metastatic eyelid disease associated with hepatocellular carcinoma. ( 17724490 )
2007
3
Eyelid disease. ( 16271321 )
2005
4
Treatment of atopic eyelid disease using topical tacrolimus following corticosteroid discontinuation in a patient with open-angle glaucoma. ( 15502487 )
2004
5
Topical tacrolimus treatment of atopic eyelid disease. ( 12614745 )
2003
6
Correlation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelial and eyelid disease. ( 11115257 )
2000
7
Mycobacterium fortuitum as a cause for nasolacrimal obstruction and granulomatous eyelid disease. ( 3574874 )
1987
8
Metastatic eyelid disease. ( 3627715 )
1987
9
Preventing eyelid disease. ( 6455407 )
1981

Variations for Eyelid Disease

Expression for Eyelid Disease

Search GEO for disease gene expression data for Eyelid Disease.

Pathways for Eyelid Disease

GO Terms for Eyelid Disease

Sources for Eyelid Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....